{"url_path":"/sec/bcli/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits****.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1137883/0001104659-26-062648-index.html","accession_number":"0001104659-26-062648","cik":"0001137883","ticker":"BCLI","issuer_name":"BRAINSTORM CELL THERAPEUTICS INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1137883/0001104659-26-062648-index.html","primary_entity_key":"0001137883","primary_entity_name":"BRAINSTORM CELL THERAPEUTICS INC."},"word_count":746,"has_tables":true,"body_markdown":"**Item 6. Exhibits****.**\n\nThe following documents are filed as exhibits to this report:\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**Incorporated by Reference Herein**\n\n​\n\n**Exhibit********Number**\n\n**  ​ ​ ​**\n\n**Description**\n\n**  ​ ​ ​**\n\n**Filed (or Furnished) with this** **Form 10-Q**\n\n**  ​ ​ ​**\n\n**Form**\n\n**  ​ ​ ​**\n\n**Exhibit** **& File No.**\n\n  ​ ​ ​\n\n**Date Filed**\n\n \n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3.1\n\n​\n\n[Certificate of Incorporation of Brainstorm Cell Therapeutics Inc.](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm)\n\n​\n\n​\n\n​\n\nDefinitive Schedule 14A\n\n​\n\nAppendix B File No. 333-61610\n\n​\n\nNovember 20, 2006\n\n​\n\n3.2\n\n​\n\n[Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated September 15, 2014.](https://www.sec.gov/Archives/edgar/data/1137883/000114420414056076/v389167_ex3-1.htm)\n\n​\n\n​\n\n​\n\nForm 8-K\n\n​\n\nExhibit 3.1 File No. 000-54365\n\n​\n\nSeptember 16, 2014\n\n​\n\n3.3\n\n​\n\n[Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated August 31, 2015.](https://www.sec.gov/Archives/edgar/data/1137883/000114420415053827/v419788_ex3-1.htm)\n\n​\n\n​\n\n​\n\nForm 8-K\n\n​\n\nExhibit 3.1 File No. 001-36641\n\n​\n\nSeptember 4, 2015\n\n​\n\n3.4\n\n​\n\n[Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated September 16, 2024.](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex3-1.htm)\n\n​\n\n​\n\n​\n\nForm 8-K\n\n​\n\nExhibit 3.1 File No. 001-36641\n\n​\n\nSeptember 16, 2024\n\n​\n\n3.5\n\n​\n\n[Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated September 30, 2024.](https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_ex3-1.htm)\n\n​\n\n​\n\n​\n\nForm 8-K\n\n​\n\nExhibit 3.1 File No. 001-36641\n\n​\n\nOctober 1, 2024\n\n​\n\n3.6\n\n​\n\n[ByLaws of Brainstorm Cell Therapeutics Inc.](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm)\n\n​\n\n​\n\n​\n\nDefinitive Schedule 14A\n\n​\n\nAppendix C File No. 333-61610\n\n​\n\nNovember 20, 2006\n\n​\n\n3.7\n\n​\n\n[Amendment No. 1 to ByLaws of Brainstorm Cell Therapeutics Inc., dated as of March 21, 2007.](https://www.sec.gov/Archives/edgar/data/1137883/000114420407014718/v069555_ex3-1.txt)\n\n​\n\n​\n\n​\n\nForm 8-K\n\n​\n\nExhibit 3.1 File No. 333-61610\n\n​\n\nMarch 27, 2007\n\n​\n\n3.8\n\n​\n\n[Amendment No. 2 to ByLaws of Brainstorm Cell Therapeutics Inc., dated as of April 20, 2025.](https://www.sec.gov/Archives/edgar/data/1137883/000110465925036851/tm2512729d1_ex3-1.htm)\n\n​\n\n​\n\n​\n\nForm 8-K\n\n​\n\nExhibit 3.1 File No. 001-36641\n\n​\n\nApril 21, 2025\n\n​\n\n10.1\n\n​\n\n[Form of Securities Purchase Agreement, dated May 11, 2026, between the Company and Vanquish Funding Group Inc.](bcli-20260331xex10d1.htm)\n\n​\n\n*\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.2\n\n​\n\n[Form of Promissory Note, issued May 11, 2026, to Vanquish Funding Group Inc.](bcli-20260331xex10d2.htm)\n\n​\n\n*\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.3\n\n​\n\n[Form of Securities Purchase Agreement, dated May 11, 2026.](bcli-20260331xex10d3.htm)\n\n​\n\n*\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.4\n\n​\n\n[Form of Common Warrant, dated May 11, 2026.](bcli-20260331xex10d4.htm)\n\n​\n\n*\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n31.1\n\n​\n\n[Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](bcli-20260331xex31d1.htm)\n\n​\n\n*\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n31.2\n\n​\n\n[Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](bcli-20260331xex31d2.htm)\n\n​\n\n*\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n32.1\n\n​\n\n[Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](bcli-20260331xex32d1.htm)\n\n​\n\n‡\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n32.2\n\n​\n\n[Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](bcli-20260331xex32d2.htm)\n\n​\n\n‡\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n101.INS\n\n​\n\nXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\n​\n\n*\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n101.SCH\n\n​\n\nInline XBRL Taxonomy Extension Schema Document\n\n​\n\n*\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n101.CAL\n\n​\n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n​\n\n*\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n101.DEF\n\n​\n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n​\n\n*\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n101.LAB\n\n​\n\nInline XBRL Taxonomy Extension Label Linkbase Document\n\n​\n\n*\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n101.PRE\n\n​\n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n​\n\n*\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n104\n\n​\n\nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n\n​\n\n*\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**Filed herewith*\n\n‡*Furnished herewith*\n\n​\n\n​\n\n43\n\n[Table of Contents](#TOC)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n​\n\n \n\n**BRAINSTORM CELL THERAPEUTICS INC.**\n\n \n\n \n\n \n\nDate: May 15, 2026\n\nBy:\n\n/s/ Chaim Lebovits\n\n​\n\n​\n\nName: Chaim Lebovits\n\n​\n\n​\n\nTitle: Chief Executive Officer\n(Principal Executive Officer)\n\n​\n\n​\n\n​\n\nBy:\n\n/s/ Alla Patlis\n\n \n\n \n\nName: Alla Patlis\n\n \n\n \n\nTitle: Controller, Interim Chief Financial Officer\n(Principal Financial Officer)\n\n​\n\n​\n\n44"}